Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.
Alternative Lengthening of Telomeres (ALT) activity can be deduced from the presence of telomere length maintenance in the absence of telomerase activity. More convenient assays for ALT utilize phenotypic markers of ALT activity, but only a few of these assays are potentially definitive. Here we assess each of the current ALT assays and their implications for understanding the ALT mechanism. We also review the clinical situations where availability of an ALT activity assay would be advantageous. The prevalence of ALT ranges from 25% to 60% in sarcomas and 5% to 15% in carcinomas. Patients with many of these types of ALT[+] tumors have a poor prognosis.
Henson
Jeremy D
JD
Children's Medical Research Institute, Sydney, NSW, Australia.
Reddel
Roger R
RR
D002277:Carcinoma / Q000201:enzymology / Q000235:genetics; D045744:Cell Line, Tumor; D017931:DNA Primers / Q000235:genetics; D004270:DNA, Circular / Q000235:genetics; D006801:Humans; D053842:Microsatellite Instability; D009369:Neoplasms / Q000201:enzymology / Q000235:genetics*; D011379:Prognosis; D011877:Radionuclide Imaging; D012509:Sarcoma / Q000000981:diagnostic imaging / Q000235:genetics; D012854:Sister Chromatid Exchange / Q000235:genetics; D019098:Telomerase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D016615:Telomere / Q000235:genetics* / Q000378:metabolism
D017931:DNA Primers; D004270:DNA, Circular; D019098:Telomerase